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Introduction
Optimal neurological recovery after suc-
cessful cardiopulmonary resuscitation 
(CPR) is the most important aspect of 
post-resuscitation care because it direct-
ly affects the final outcome. Proper oxy-
genation, blood pressure control, normo-
glycemia and therapeutic hypothermia 
are established measures in immediate 
post-resuscitation care, which promote 
variable degrees of cerebral recovery. 
A brief period of cerebral hyperemia 
after return of spontaneous circulation 
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ABSTRACT
Studies show that erythropoietin, besides its critical role in hematopoiesis, provides neuroprotection in hypoxic-ischemic 
cerebral injury. Antiapoptotic, anti-inflammatory, angiogenetic, and neurotrophic properties of erythropoietin could increase 
indications, currently restricted to anemia in chronic renal failure and cancer, to hypoxic-ischemic cerebral insult. 
In the adult and neonatal animal model of hypoxic-ischemic cerebral injury, erythropoietin significantly reduces infarct size 
with attenuation of brain damage, and preservation of  cortical integrity. The first human study on the impact of erythropoi-
etin in stroke victims showed that erythropoietin is safe and well tolerated at high doses, and associated with improved 
neurological outcome. Even with intravenous application, concentrations of erythropoietin in cerebrospinal fluid of these 
patients were many-fold higher than in non-treated patients. 
In successfully resuscitated cardiac arrest victims overall neurological recovery remains poor despite improved cardiopul-
monary resuscitation strategies. Post-resuscitation care needs further advances in order to improve final outcome. Through 
promotion of neuroangiogenesis, inhibition of hypoxia-induced apoptosis in neurons, and thus support of the survival of 
neurons in the ischemic brain, erythropoietin could be used to improve functional recovery of these patients. Nevertheless, 
optimal molecular forms of EPO, therapeutic doses, and treatment time window have to be determined in order to lower 
the incidence of adverse effects and still preserve neuroprotective properties. 
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(ROSC) (1) is followed by decreased 
brain perfusion. Unstable, post-resus-
citation hemodynamics, together with 
the initial hypoxic-ischemic injury, lead 
to further neurological damage. Despite 
the increased incidence of ROSC and 
overall survival, poor functional recov-
ery of successfully resuscitated cardiac 
arrest victims demands further research 
in the field of post-resuscitation care. 
Exogenous erythropoietin (EPO) has 
been shown to promote neuroprotection 
in hypoxic-ischemic cerebral insult by 
regulating neurogenesis, and prevent-
ing neuronal apoptosis (2-4). These pro-
tective properties of EPO, in ischemic 
brain damage, could benefit patients 
who have survived a cardiac arrest.
Neuroprotective role of 
erythropoietin in cerebral 
ischemia 
As nature proves, the simplest and 
yet the most important solutions lie in 
the capability of nature to renew itself 
from its own resources. EPO, a vital 
compound of erythroid differentiation, 
is also involved in non-hematopoiet-
ic tissue protective pathways with its 
antiapoptotic, anti-inflammatory, ang-
iogenetic, and neurotrophic properties 
(5). The evidence shows that hypoxia 
increases production of EPO not only 
in kidneys, but also in brain, testis, liver, 
and spleen (6-8). In brain, EPO is high-
ly expressed after neuropathological 
insult (6). Astrocytes produce EPO after 
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its upregulation due to hypoxia, and 
neurons express EPO receptors (3,8). 
It has also been shown that after sys-
temic administration, EPO promotes 
neuroprotection even in severe cerebral 
ischemia (9), enhances neurological 
recovery in traumatic brain and spinal 
cord injury (6,10-13), and prevents the 
loss of autoregulation of cerebral blood 
flow (14). This evidence of neuroprotec-
tion and restructuring of cerebral tissue 
after neuropathological insult could be 
the rationale for using EPO in clinical 
practice to limit neuronal damage (15).
Even though the blood-brain barrier 
prevents transport of systemic EPO into 
brain, hypoxic-ischemic brain condi-
tions disrupt the blood-brain barrier, 
making brain cells accessible to intra-
venously administered EPO (16). There 
is an increasing body of evidence sug-
gesting that EPO crosses the blood-
brain barrier in human and animal 
models, after peripheral application 
(4,6,14,17-21). Usefulness of EPO as a 
therapeutic agent in hypoxic-ischemic 
cerebral conditions is thus based on 
its capability to cross the blood-brain 
barrier, upregulation of its expression 
in hypoxic conditions, neuroprotective 




resuscitation: are we near? 
Cerebral ischemia is inevitable dur-
ing cardiac arrest and at some extent 
during the post-resuscitation period. 
During the first few hours of recovery 
from cardiac arrest, the brain remains 
hypoxic, but for no more than 2 days 
(23). After a hypoxic-ischemic insult, 
hypoxia inducible factor (HIF) isoforms, 
HIF-1 alpha and HIF-2 alpha, stimulate 
the expression of EPO in brain astro-
cytes (23-25). In the brain, HIF-1 alpha 
accumulates early during recovery from 
cardiac arrest, and persists for several 
days after successful resuscitation (23). 
Intrinsic EPO, produced by the majority 
of brain cells after HIF stimulation (26), 
and exogenous EPO, protect neuro-
nal tissue from oxygen deprivation and 
other noxious stimuli, promote neuroan-
giogenesis, inhibit hypoxia-induced 
apoptosis in neurons, and thus support 
the survival of neurons in the ischemic 
brain (4,16,25-29).
In the proximity of infarcted areas of the 
brain there is a degree of angiogenesis, 
axonal reorganization with neurogen-
esis, and neuroblast migration to areas 
exposed to ischemic injury, which is in 
part mediated by EPO (30,31). In an 
adult animal model of ischemic stroke, 
exogenous EPO reduces an infarct 
size (2,4,17,26,32). In the neonatal ani-
mal model, exogenous EPO improves 
asymmetry of forelimbs following stroke 
(18), reduces the infarct size with atten-
uation of brain injury, and preserves the 
integrity of cerebral cortex (33,34).  
EPO induces time- and dose-depend-
ent tolerance against oxygen and glu-
cose deprivation in primary cortical 
neurons and protects from cell death. 
The protection is significant within min-
utes and lasts up to 48 hours after con-
tinued EPO exposure (27). In vivo, the 
protective properties are most promi-
nent when EPO is given early after focal 
or global cerebral hypoxic-ischemic 
insult, which in turn improves long-
term neurobehavioral achievements 
(17,32,33,35,36). The therapeutic time 
window for tissue protection by EPO is 
very wide in experimental models (37).
This evidence makes EPO a potent ther-
apeutic agent for neurological emergen-
cies with the purpose to improve func-
tional recovery (25,26,30), and could 
also present a rationale for  treatment 
with EPO after successful CPR. 
What does the future hold?
A pioneer work by Ehrenreich et al. (19), 
regarding the impact of EPO on hypoxic-
ischemic cerebral damage in humans, 
showed that intravenous high-dose 
recombinant EPO, a total of 100.000 
units given in the first three days after 
acute ischemic stroke, is well tolerated 
and improves clinical outcome. Evi-
dence shows that doses of at least 500 
units/kg of body weight of EPO given 
intravenously, offer significant tissue 
protection, and that tissue-protecting 
properties of EPO start at peak serum 
concentrations of 50 ng/ml for central 
nervous system lesions (38). 
In the central nervous system, tissue 
protecting mechanisms require doses 
that are higher than those for stimula-
tion of erythropoiesis (5), while in other 
tissues like heart, cytoprotection could 
be accomplished with lower doses 
(39). Nevertheless, optimal recom-
binant EPO or its analogues, dose 
characteristics, and the therapeutic 
window for EPO use in humans have 
to be determined yet in order to pro-
vide appropriate tissue protection, and 
lower the incidence of adverse effects. 
The later mainly consist of increased 
hematocrit and platelet aggregability 
which significantly increases the risk of 
thrombosis (5), and high-risk patients 
are those with polycythemia–hypervis-
cosity syndrome, hypertension, and 
vascular thrombosis (40). Non-eryth-
ropoietic tissue-protective derivates of 
EPO, like asialo EPO and carbamylated 
EPO, still provide neuroprotection, and 
avoid adverse effects at the same time 
(36,40-42). 
In summary, upregulation of EPO in 
hypoxic-ischemic human brain, ability 
of exogenous EPO to cross the blood-
brain barrier after peripheral applica-
tion, its neuroprotective role in animal 
and human studies, pleiotrophism, and 
clinical tolerance give a strong rationale 
for further research of the impact of 
EPO on neurological recovery after suc-
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